Fig. 1.

Dose-dependent enhancement of natural killer (NK) cell-mediated cytotoxicity of antibody-coated tumor cells by lenalidomide: a cetuximab-coated HCT-116 and HT-29 colorectal cancer cells (E:T cell ratio 10:1); and b trastuzumab-coated SK-BR-3 and MCF-7 breast cancer cells (E:T cell ratio 10:1). Data are expressed as % tumor cell killing (mean ± SD of three individual experiments each performed in triplicate). Asterisks indicate significant difference between the killing of antibody-coated target cells versus uncoated target cells, by lenalidomide pre-treated NK cells (*P < 0.05; **P < 0.01; two-way ANOVA with Bonferroni post hoc test)